share_log

Barclays Maintains Overweight on Replimune Group, Lowers Price Target to $13

Barclays Maintains Overweight on Replimune Group, Lowers Price Target to $13

巴克萊維持對Replimune集團的增持,將目標股價下調至13美元
Benzinga ·  2023/12/06 06:36

Barclays analyst Peter Lawson maintains Replimune Group (NASDAQ:REPL) with a Overweight and lowers the price target from $50 to $13.

巴克萊分析師彼得·勞森維持Replimune集團(納斯達克股票代碼:REPL)增持 “增持”,並將目標股價從50美元下調至13美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論